Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aptorum Group Ltd APM

Healthcare Biotechnology
Aptorum Group Limited is a United Kingdom-based clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which... see more

Recent & Breaking News (NDAQ:APM)

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020

Business Wire October 16, 2020

Aptorum Group Announces Closing of $9.0 Million Public Offering

Business Wire October 2, 2020

Aptorum Group Announces Pricing of $9.0 Million Public Offering

Business Wire September 29, 2020

Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Genome

Business Wire September 29, 2020

Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10

Business Wire September 8, 2020

Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance

Business Wire September 8, 2020

Aptorum Group Announces Video Update Discussing Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types

Business Wire September 2, 2020

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020

Business Wire September 1, 2020

Aptorum Group Announces Further Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types

Business Wire September 1, 2020

Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models

Business Wire September 1, 2020

LD Micro - 360 Companies Set to Present this Week

Accesswire August 31, 2020

Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report

Business Wire August 28, 2020

Aptorum Group Limited to Present at The LD 500 Virtual Conference and H.C. Wainwright 22nd Annual Global Life Sciences Conference

Business Wire August 26, 2020

Aptorum Group Appoints Dr. Herman Weiss as CEO of microbiome-based platform Claves Life Sciences and Dr. Robbie Majzner as scientific advisor to SACT-1 drug for Neuroblastoma and others

Business Wire August 20, 2020

LD Micro Announces Preliminary List of Presenters for the LD 500

Accesswire August 5, 2020

Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext Paris Stock Exchange Under the Ticker Symbol APM

ACN Newswire July 27, 2020

Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext Paris Stock Exchange Under the Ticker Symbol APM

Business Wire July 24, 2020

Aptorum Group Prospectus Receives Approval for Listing on the Euronext Paris Stock Exchange

Business Wire July 17, 2020

Aptorum Group Limited Strengthens Its Presence in the US With the Appointment of Dr. Kira Sheinerman

Business Wire June 15, 2020

Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report

Business Wire May 29, 2020